Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 938

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 938
---
2%  | ​ | ​ | ​ |                 ​ | ​ | —   | ​ | ​ |
| Vendor C | ​ | ​ |                                      ​ | ​ | 2%  | ​ | ​ | ​ |    ​ | ​ | 11% | ​ | ​ | ​ |                    ​ | ​ | —   | ​ | ​ | ​ |                 ​ | ​ | 10% | ​ | ​ |
| Vendor D | ​ | ​ |                                      ​ | ​ | —   | ​ | ​ | ​ |    ​ | ​ | —   | ​ | ​ | ​ |                    ​ | ​ | —   | ​ | ​ | ​ |                 ​ | ​ | 19% | ​ | ​ |
| ​        | ​ | ​ |                                      ​ | ​ | 64% | ​ | ​ | ​ |    ​ | ​ | 66% | ​ | ​ | ​ |                    ​ | ​ | 85% | ​ | ​ | ​ |                 ​ | ​ | 69% | ​ | ​ |

The Company’s preclinical studies and clinical trials and testing could be adversely affected by a significant interruption in the supply chain from its significant suppliers. Cash and Cash Equivalents The Company considers all highly liquid investments, with an original maturity of three months or less, to be cash equivalents. Cash equivalents include amounts held in money market funds in the amount of $8.8 million and $21.8 million as of September 30, 2024 and December 31, 2023, respectively. The Company recorded interest income on its cash equivalents of $0.6 million for the nine months ended September 30, 2024 on its statements on operations. The Company recorded interest income of $1.0 million on its cash equivalents and previously outstanding short-term investments during the nine months ended September 30, 2023 on its statements of operations. The $1.0 million is also inclusive of accretion of its discounts on its short-term investments, which fully matured during fiscal 2023 Deferred Offering Costs The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in process transactions, such as mergers or equity financings, as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded as a reduction of the proceeds from the offering, either as a reduction of the carrying value of the preferred stock or in stockholders’ deficit as a